Extended Data Fig. 6: ChromBPNet validation in other enhancers.
From: In vivo mapping of mutagenesis sensitivity of human enhancers
(A) Predictive (Ma 2024 medRxiv, Pampari 2025 bioRxiv) and post-hoc (remaining examples) analysis of mutational impact predictions in enhancers tested in vivo19,55,56,57,58. In all cases a prediction consistent with the impact in vivo was obtained. (B) Model predicted signal change and observed in vivo impact of 147 mutagenized ZRS with PPV = 83% and sensitivity = 25% or 137 brain mutagenized enhancer elements with PPV = 78% and sensitivity = 51%2,10. See Supplementary Note 4 for same cutoff scoring method applied to block mutagenesis, at abs(log2FC)>0.32 (25% signal increase).
